Galderma Research & Development Patent applications |
Patent application number | Title | Published |
20150376126 | METHOD FOR THE SYNTHESISING 4-PIPERIDIN-4-YL-BENZENE-1,3-DIOL AND THE SALTS OF SAME AND NOVEL COMPOUND TERT-BUTYL 4-(2,4-DIHYDROXY-PHENYL)-4-HYDROXY-PIPERIDINE-1-CARBOXYLATE - A method is described for the synthesis of 4-piperidin-4-yl-benzene-1,3-diol of the following formula (I): | 12-31-2015 |
20150190323 | SELECTIVE COMPOUNDS INHIBITING CYP26A1 USEFUL IN COSMETIC AND PHARMACEUTICAL COMPOSITIONS - Compounds or salts thereof are described that correspond to general formula (I) below: | 07-09-2015 |
20150150974 | TOPICAL COMPOSITIONS OF AQUEOUS GEL TYPE IN THE FORM OF A HOMOGENEOUS SUSPENSION OF AN ACTIVE PRINCIPLE OF THE RETINOID CLASS CONTAINING AT LEAST ONE HYDROPHOBIC SILICA - Aqueous-gel type topical compositions are described. The compositions can be in the form of a homogeneous suspension of an active principle of the class of retinoids including at least one hydrophobic silica, the active principle preferably having general formula (I), and more specifically being 3″-tert-butyl-4′-(2-hydroxy-ethoxy)-4″-pyrrolidin-1-yl-[1,1′3′,1″]-terphenyl-4-carboxylic acid. Also described, is the preparation mode thereof and the use of same in the treatment of dermatological conditions. | 06-04-2015 |
20150148400 | O/W-EMULSION-TYPE TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING A RETINOID - O/W-emulsion-type topical pharmaceutical compositions including a retinoid are described. Also described, is a topical pharmaceutical composition including by way of an active pharmaceutical ingredient, a retinoid in a physiologically acceptable composition. Preparation methods and the use of the same in dermatology are also described. | 05-28-2015 |
20150125520 | LIPID NANOCAPSULES COMPRISING A RETINOID, NANODISPERSION AND COMPOSITION CONTAINING THE SAME, PROCESS FOR PREPARING THE SAME AND USE THEREOF IN DERMATOLOGY - Lipid nanocapsules are described that include at least one irritating active ingredient, and more specifically a retinoid in solubilized form. Also described, are nanodispersions and pharmaceutical compositions including the same and methods of producing the same. The use of the pharmaceutical compositions in the treatment of dermatological pathologies is also described. | 05-07-2015 |
20140371163 | COMBINATION THERAPY FOR ACNE VULGARIS COMPRISING ADMINISTRATION OF ADAPALENE 0.3% GEL AND CLINDAMYCIN/BENZOYL PEROXIDE GEL - A novel regime or regimen for the treatment of acne related diseases and particularly acne vulgaris includes administering to a patient in need of such treatment a therapeutically effective amount of Differin gel 0.3% (adapalene) in association or combination with a combined clindamycin/benzoyl peroxide gel product such as DUAC®. | 12-18-2014 |
20140349866 | NEW TH-17 DIFFERENTIATION MARKERS FOR ROSACEA AND USES THEREOF - Methods are described for using genes crucial in TH17 differentiation, IL-12Rbeta 1/IL-23R, CCR6, BATF, AHR, STAT3 and IRF4 as new markers for rosacea. Also described, are methods of their use to diagnose rosacea, to screen inhibitors of Th17 differentiation. In particular, method are described for inhibiting at least one of these genes and using the screened inhibitors in rosacea treatment. | 11-27-2014 |
20140329809 | NEW LEUKOCYTE INFILTRATE MARKERS FOR ROSACEA AND USES THEREOF - A process for the characterization of rosacea is disclosed. The process can include identifying for the first time new markers in leukocyte recruitment as well as the therapeutic applications targeting rosacea. | 11-06-2014 |
20140308223 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 10-16-2014 |
20140296254 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES - Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are described that correspond to general formula (I). Also described, are pharmaceutical compositions that include these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated diseases. | 10-02-2014 |
20140275536 | NOVEL PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF - The use of compounds in the treatment of skin disorders is described. In particular, use of a compound of formula (I): | 09-18-2014 |
20140275108 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS - Provided herein are novel benzenesulfonamide compounds having a structure of formula (I) below: | 09-18-2014 |
20140249232 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 09-04-2014 |
20140249096 | COMBINATION OF COMPOUNDS FOR TREATING OR PREVENTING SKIN DISEASES - A combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea is described. The combination of a compound of the avermectin family or of the mylbemycin family with a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists is also described. In addition, a product in the form of a kit including: (a) a first composition containing a compound of the avermectin family or of the mylbemycin family, and (b) a second composition different from the first one and containing a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists, as a combination product to be used as a drug for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay, is described. | 09-04-2014 |
20140243523 | HUMAN EPITHELIAL CELL LINE FOR 3-D MODELIZING OF CANCER AND TREATMENT THEREOF - A cellular model is described that targets dysregulation or inappropriate activation of the Sonic Hedgehog/Patched (SHH/PTCH) pathway. Also described, is a screening method using this cellular model to screen for pharmacological compounds that can treat or prevent skin cancer, in particular, Basal Cell Carcinoma (BCC) lesions. | 08-28-2014 |
20140234852 | HUMAN KERATINOCYTES PTCH1 CELL LINE - A cellular model is described for targeting dysregulation or inappropriate activation of the Sonic Hedgehog/Patched (SHH/PTCH) pathway. Also described, is a screening method using this cellular mod& to screen for pharmacological compounds that can treat or prevent skin cancer and, in particular, Basal Cell Carinoma (BCC) lesions. | 08-21-2014 |
20140234245 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE - N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides of formula (1) are described that are potent modulators (e.g., inhibitors) of an androgen receptor, and which are useful, for example, in the treatment of a dermatological disease or disorder; a disease or disorder of the sebaceous gland(s); acne; hyperseborrhoea; oily skin, seborrhoeic dermatitis; hyperpilosity or hirsutism; atopic dermatitis; or androgenic alopecia; especially acne. Also described, are compositions (e.g., pharmaceutical compositions, cosmetic compositions) comprising the compounds; methods of preparing the compositions; methods of modulating (e.g., inhibiting) and androgen receptors using the compounds and/or compositions; and medical and/or cosmetic use of the compounds and compositions. | 08-21-2014 |
20140221231 | TH-17 DIFFERENTIATION MARKERS FOR ROSACEA AND USES THEREOF - A method is described that uses ROR gamma t, or ROR alpha to diagnose rosacea and/or to screen inhibitors of Th17 differentiation, notably in inhibiting ROR gamma t or ROR alpha. Also described is a method of using these screened inhibitors in rosacea treatment. | 08-07-2014 |
20140205589 | NEW STABLE ANESTHETIC COMPOSITION FOR REDUCING SKIN REACTIONS - A composition is described with reduced degradation rate and/or improved stability of its components. The composition can alleviate or even annihilate cutaneous reactions and can include an emulsion with an oil phase and an aqueous phase, wherein the oil phase can be a eutectic mixture of at least one anesthetic compound and at least one adrenergic receptor agonist. Methods of using such a composition are also described. | 07-24-2014 |
20140187532 | 4-(AZACYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS - 4-(azacycloalkyl)benzene-1,3-diol compounds are described corresponding to general formula (I) below: | 07-03-2014 |
20140162291 | IN VITRO METHOD USING HUMAN SKIN FOR EVALUATING THE INFLUENCE OF ABC TRANSPORTERS - An in vitro method is described that uses full-thickness human skin for evaluating the influence of ABC transporters (such as MDR1, MRP1, MRP2 or BCRP) on the absorption and distribution of topically applied medicinal substances. | 06-12-2014 |
20140148417 | COMPOSITIONS COMPRISING A FILLER PRODUCT AND A COMPOUND OF THE TETRACYCLINE FAMILY USED AT A SUBANTIMICROBIAL DOSE - A combination product is described. The combination product can include composition “A”, which can have at least one filler product and a composition “B”, which can have at least one compound of the tetracycline family used at a subantimicrobial dose for the treatment of skin aging and scars. Compositions “A” and “B” can be used simultaneously, separately or sequentially over time. Also described, is a single pharmaceutical composition having, in the same physiologically acceptable medium, at least one filler product and at least one compound of the tetracycline family used at a subantimicrobial dose. | 05-29-2014 |
20140142062 | PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISING HYALURONIC ACID AND TREATMENT OF DERMATOLOGICAL CONDITIONS THEREWITH - Pharmaceutical/cosmetic compositions containing a dermatologically effective amount of hyaluronic acid, at least one retinoid and/or salt and/or derivative thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, formulated into a physiologically acceptable medium therefor, are useful for the treatment of wrinkles, fine lines, fibroblast depletions and scars. | 05-22-2014 |
20140107129 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS - Benzenesulfonamide compounds having a structure of formula (I) are described. Also described, are methods for synthesizing the compounds and to the use thereof in pharmaceutical compositions for human or veterinary medicine and in cosmetic compositions. | 04-17-2014 |
20140094469 | METHODS AND COMPOSITIONS FOR SAFE AND EFFECTIVE TREATMENT OF ERYTHEMA - Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier. | 04-03-2014 |
20140065221 | COMPOSITIONS COMPRISING A FILLER PRODUCT AND AT LEAST ONE BIORESORBABLE AND BIODEGRADABLE SILICA-BASED MATERIAL - A combination product including at least one filler product and at least at least one bioresorbable and biodegradable silica-based material, for treating incontinence or treating aging of the skin and scars. Also, a composition including, in a physiologically acceptable medium, at least one filler product and at least at least one bioresorbable and biodegradable silica-based material. | 03-06-2014 |
20140031427 | COMBINATIONS OF ADAPALENE AND BENZOYL PEROXIDE FOR TREATING ACNE LESIONS - Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO. | 01-30-2014 |
20140031341 | MODULATORS AND METHODS FOR THE TREATMENT OF ROSACEA - An in vitro method of screening candidate compounds for the preventive or curative treatment of rosacea is described. The method can include determining the capacity of a compound to modulate the expression or activity of the Transient Receptor Potential (TRPs), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of rosacea. The method can also include in vitro diagnosis or prognosis of this pathology. | 01-30-2014 |
20140010884 | DERMATOLOGICAL COMPOSITIONS COMPRISING RETINOIDS, DISPERSED BENZOYL PEROXIDE AND CARRAGEENANS - Dermatological compositions containing, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and at least one gelling agent of the family of the carrageenans, are useful for treating dermatological conditions and afflictions linked to disorders of cell differentiation and/or proliferation and/or keratinization, notably for treating acne vulgaris. | 01-09-2014 |
20130345542 | DETERMINATION BY INDEPENDENT COMPONENT ANALYSIS OF THE EFFICACY OF A TREATMENT - A method is described for determining a value for quantifying the deviation from a mean value of a distribution of a divergence in severity between an initial instant and a later instant subsequent to the initial instant. | 12-26-2013 |
20130338235 | DERMATOLOGICAL FOAMS OBTAINED FROM A GEL OR SUSPENSION CONTAINING BENZOYL PEROXIDE - Intermediate compositions, and in particular gels and suspensions for preparing foam compositions, are described. The compositions can include benzoyl peroxide. Also described, is the dermatological use of such compositions. | 12-19-2013 |
20130331428 | TOPICAL COMPOSITIONS CONTAINING A RETINOID OF THE OIL-IN-WATER EMULSION TYPE - A composition in the form of an oil in water emulsion, preferably without emulsifier, is described. The composition can include, in a physiologically acceptable environment, at least one new retinoid. Also described, is the method of preparing the composition and its use in cosmetics and dermatology. | 12-12-2013 |
20130317108 | DERMATOLOGICAL FOAMS OBTAINED FROM A GEL OR SUSPENSION CONTAINING A COMBINATION OF ADAPALENE AND BENZOYL PEROXIDE - Intermediate compositions, and in particular gels and suspensions for foam compositions, are described that include adapalene and benzoyl peroxide in combination. Also described; is the dermatological use of such compositions. | 11-28-2013 |
20130253062 | COMBINATIONS OF ADAPALENE AND BENZOYL PEROXIDE FOR TREATING ACNE LESIONS - Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO. | 09-26-2013 |
20130245123 | COSMETIC/DERMATOLOGICAL COMPOSITIONS COMPRISING NAPHTHOIC ACID COMPOUNDS AND POLYURETHANE POLYMERS - Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein. | 09-19-2013 |
20130231393 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA - A compound of formula (I): | 09-05-2013 |
20130217740 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA - A compound of formula (I): | 08-22-2013 |
20130203850 | METHOD FOR TREATING SCARS WITH ADAPALENE 0.3% - A method is described for treating a scar with an effective amount of adapalene or salts thereof, which is administrated to the patient in need thereof. Optionally, the administered adapalene is in a quantity of 0.3% by weight relative to the total weight of the composition. | 08-08-2013 |
20130197048 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA - A compound of formula (I): | 08-01-2013 |
20130178648 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE - Compounds of the following general formula (I): | 07-11-2013 |
20130178633 | PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF - The use of compounds in the treatment of skin disorders is described. In particular, use of a compound of formula (I): | 07-11-2013 |
20130172564 | PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF - The use of compounds in the treatment of skin disorders is described. In particular, use of a compound of formula (I): | 07-04-2013 |
20130172363 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS - Benzenesulfonamide compounds having a structure of formula (I) are described. Also described, are methods for synthesizing the compounds and to the use thereof in pharmaceutical compositions for human or veterinary medicine and in cosmetic compositions. | 07-04-2013 |
20130158090 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA - A compound of formula (I): | 06-20-2013 |
20130137656 | PHARMACEUTICAL/ COSMETIC COMPOSITION COMPRISING HYALURONIC ACID AND TREATMENT OF DERMATOLOGICAL CONDITIONS THEREWITH - Pharmaceutical/cosmetic compositions containing a dermatologically effective amount of hyaluronic acid, at least one retinoid and/or salt and/or derivative thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, formulated into a physiologically acceptable medium therefor, are useful for the treatment of wrinkles, fine lines, fibroblast depletions and scars. | 05-30-2013 |
20130131177 | USE OF A DERMATOLOGICAL COMPOSITION COMPRISING A COMBINATION OF ADAPALENE AND BENZOYL PEROXIDE WHICH IS INTENDED FOR THE TREATMENT OF ACNE IN NON-CAUCASIAN POPULATION WITH DECREASE OF POST-INFLAMMATORY HYPERPIGMENTATION - A dermatological composition including a combination of Adapalene and benzoyl peroxide is described. The composition is intended for the treatment of acne in the non-Caucasian population with decreased post-inflammatory hyperpigmentation, keloid scarring and acne hyperpigmented macules and cystic lesions. | 05-23-2013 |
20130116259 | COMBINATION THERAPY FOR TREATING OR PREVENTING AN INFLAMMATORY SKIN DISORDER - Methods and compositions for improved treatment and prevention of an inflammatory skin disorder or a sign and/or symptom associated with the skin disorder are described. The methods involve topical application to the skin a combination of a therapeutically effective amount of an α2 adrenergic receptor agonist, such as brimonidine, and a therapeutically effective amount of a non-steroidal anti-inflammatory agent, such as diclofenac. | 05-09-2013 |
20130079544 | DIBENZOYL PEROXIDE DERIVATIVES, PREPARATION METHOD THEREOF AND COSMETIC OR DERMATOLOGICAL COMPOSITIONS CONTAINING SAME - The use of compounds in the treatment of skin disorders is described. In particular, compounds having the general formula (I): | 03-28-2013 |
20130046022 | GEL COMPOSITION FOR TREATMENT OF COMMON ACNE COMPRISING A COMBINATION OF BENZOYL PEROXIDE AND ADAPALENE AND/OR ADAPALENE SALT - Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, selected from the group consisting of (a) polyacrylamide gelling agents, (b) gelling agents which are acrylic polymers coupled to hydrophobic chains, (c) modified starch gelling agents, and mixture thereof, said composition maintaining good chemical stability of (i) and (ii) without their degradation over time at a temperature of between 4° C. and 40° C. | 02-21-2013 |
20130041035 | TOPICAL APPLICATION OF ADAPALENE FOR THE LONG-TERM TREATMENT OF ACNE VULGARIS - Administration of adapalene in a topical medicament to a patient so as to sustain its biological response in the treatment of acne vulgaris, wherein the administration pattern of the topical medicament comprises topically applying onto the afflicted skin area a therapeutically effective amount of adapalene at least once every two days for at least 6 months. | 02-14-2013 |
20130039995 | DERMATOLOGICAL COMPOSITIONS COMPRISING AT LEAST ONE REINOID COMPOUND, AN ANTI-IRRITANT COMPOUND AND BENZOYL PEROXIDE - Dermatological compositions contain, formulated into a physiologically acceptable medium, at least one retinoid compound selected from among all-trans retinoic acid, isotretinoin, motretinide, and naphthoic acid compounds of formula (I), and salts and esters thereof: | 02-14-2013 |
20130023516 | 4-(AZACYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS - 4-(azacycloalkyl)benzene-1,3-diol compounds are described corresponding to general formula (I) below: | 01-24-2013 |
20130017969 | MARKERS AND METHOD FOR THE DIAGNOSIS OF ROSACEA - Markers for rosacea among the chemokines and cytokines and their receptors, selected from interleukin 8 (IL-8), CXCL1, CXCL2, CXCL3 and CXCL5, the CXCR1 receptor and the CXCR2 receptor are described. Also described, is a method for the diagnosis of rosacea. | 01-17-2013 |
20130005803 | USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SKIN DISORDERS - The use of compounds in the treatment of skin disorders is described. In particular, the use of a compound of formula (I) | 01-03-2013 |
20120323035 | NOVEL PEROXIDE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR USE IN HUMAN MEDICINE AND IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE - Compounds of the following general formula (I): | 12-20-2012 |
20120323012 | 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF - 4-(azacycloalkyl)-benzene-1,3-diol compounds with the following general formula (I): | 12-20-2012 |
20120323006 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS - Benzenesulfonamide compounds having a structure of formula (I) are described. Also described, are methods for synthesizing the compounds and to the use thereof in pharmaceutical compositions for human or veterinary medicine and in cosmetic compositions. | 12-20-2012 |
20120322829 | USE OF A DIPYRIDYL COMPOUND FOR TREATING ROSACEA - A compound of formula (I) below: | 12-20-2012 |
20120309753 | METHOD OF DISSOLVING ANTIFUNGAL AGENT, AND COMPOSITIONS WITH A HIGH CONCENTRATION OF ANTIFUNGAL AGENT, SUITABLE FOR APPLICATION TO THE NAIL - A pharmaceutical composition is described which includes: an antifungal agent from the class of the allylamines or the morpholines, at a concentration of at least 5%; a ternary solvent system comprising water; at least one branched or straight chain C2-C8 alkanol; at least one glycol; the total amount of water representing more than 30% (w/w) of the composition. This composition is intended for application to the nail for the treatment of onychomycoses. | 12-06-2012 |
20120295914 | COMBINATION OF ADRENERGIC RECEPTOR AGONIST ALPHA-1 OR ALPHA-2, PREFERABLY BRIMONIDINE WITH FILLERS, PREFERABLY HYALURONIC ACID - A combination of a quantity of adrenergic receptor agonist α-1 or α-2, and preferably product known as brimonidine, with fillers, and preferably with hyaluronic acid, for decreasing skin or cutaneous reactions is described. | 11-22-2012 |
20120282314 | DERMATOLOGICAL/COSMETIC SKIN DEPIGMENTING COMPOSITIONS - Depigmenting compositions having improved effectiveness in the dermatological or cosmetic treatment of pigmentation contain, in a physiologically acceptable medium, at least one compound selected from among rucinol and salts thereof, and at least one retinoid; such compositions are also useful in the prevention and/or dermatological treatment of skin hyperpigmentation, and also for the cosmetic treatment of photoinduced or chronological aging of the skin or of the skin appendages. | 11-08-2012 |
20120270941 | TOPICAL APPLICATION OF TRAVOPROST FOR COMBATING HAIR LOSS - Travoprost medicament compositions for non-daily topical application are useful for simulating or inducing the growth and/or decreasing the loss and/or increasing the density and/or reducing the heterogeneity in the diameter of human hair shafts/follicles, e.g., for the treatment of androgenic alopecia, such medicament compositions being at least twice applied over a time interval of greater than 24 hours. | 10-25-2012 |
20120258996 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS - Novel ligand compounds having the general formula (I): | 10-11-2012 |
20120226033 | 4-ALKOXY-N- (2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL) -BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES - The present invention relates to novel benzene-carboxamide compounds having a structure that corresponds to the general formula (I) below: and also to their method of synthesis and to their use in pharmaceutical compositions intended for use in human or veterinary medicine or else to their use in cosmetic compositions. | 09-06-2012 |
20120214869 | NOVEL LIGAND ACTIVATORS OF THE RAR RECEPTORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF - Novel ligand compounds having the structural formula (I): | 08-23-2012 |
20120178934 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS - The present invention relates to novel benzene-carboxamide compounds having a structure that corresponds to the general formula (I), and also to their method of synthesis and to their use in pharmaceutical compositions intended for use in human or veterinary medicine or else to their use in cosmetic compositions. | 07-12-2012 |
20120136059 | COMBINATIONS OF ADAPALENE AND BENZOYL PEROXIDE FOR TREATING ACNE LESIONS - Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO. | 05-31-2012 |
20120135937 | INJECTABLE COMBINATION OF ADRENERGIC RECEPTOR AGONISTS WITH FILLERS, FOR DECREASING SKIN REACTIONS DUE TO INJECTION - The present invention concerns an injectable composition comprising a filler or a botulinum toxin and an adrenergic receptor agonist, and its use for diminishing, decreasing or avoiding skin reactions due to injection, specially redness, ecchymosis, bruising, bleeding, erythema, oedema, necrosis, ulceration, swelling and/or inflammation. | 05-31-2012 |
20120123275 | INFRARED IMAGING OF CUTANEOUS MELANOMA - A process is described for identifying and classifying cutaneous melanoma of a lesion on the skin of a subject by a FTIR spectrometer coupled with a micro-imaging system. | 05-17-2012 |
20120121527 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARy TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF - Novel biaromatic compounds having the general formula (I): | 05-17-2012 |
20120115947 | COMBINATION/ASSOCIATION OF ADAPALENE AND BENZOYL PEROXIDE FOR TREATING ACNE LESIONS - Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO). | 05-10-2012 |
20120077970 | METHOD FOR PREPARING MOLECULAR COMPLEXES BETWEEN ADAPALENE AND CYCLODEXTRINS - A method for preparing molecular complexes between Adapalene and cyclodextrins using the technology of dense fluids under pressure, especially that of CO2 is described. | 03-29-2012 |
20120059063 | COMBINATIONS OF ADAPALENE AND BENZOYL PEROXIDE FOR TREATING ACNE LESIONS - Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO. | 03-08-2012 |
20120045500 | NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM - Compounds of general formula (I): | 02-23-2012 |
20120041213 | 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS - 4-(heterocycloalkyl)benzene-1,3-diol compounds are described corresponding to general formula (I) below: | 02-16-2012 |
20120035123 | COMBINATION OF COMPOUNDS FOR TREATING OR PREVENTING SKIN DISEASES - A combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea is described. The combination of a compound of the avermectin family or of the mylbemycin family with a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists is also described. In addition, a product in the form of a kit including: (a) a first composition containing a compound of the avermectin family or of the mylbemycin family, and (b) a second composition different from the first one and containing a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists, as a combination product to be used as a drug for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay is described. | 02-09-2012 |
20120021017 | N-PHENYLACETAMIDE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM - Compounds of general Formula (I), | 01-26-2012 |
20120021016 | NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM - Compounds of general Formula (I), | 01-26-2012 |
20120016031 | BIPHENYL COMPOUND SELECTIVE AGONISTS OF GAMMA RAR RECEPTORS - Biphenyl compounds having the formula (I): | 01-19-2012 |
20110319491 | ANHYDROUS DEPIGMENTING COMPOSITIONS COMPRISING, WITHIN THE FATTY PHASE THEREOF, A SOLUBILIZED PHENOLIC COMPOUND AND A RETINOID - Novel anhydrous dermatological depigmenting compositions, especially for topical application, contain, within the fatty phase thereof, as pharmaceutical active agents, a dissolved phenolic compound and a retinoid. | 12-29-2011 |
20110318396 | DERMATOLOGICAL/COSMETIC COMPOSITIONS COMPRISING A RETINOID AND BENZOYL PEROXIDE - Dermatological/cosmetic compositions contain, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and a gelling system comprising at least two categories of compounds. | 12-29-2011 |
20110311466 | NOVEL 4-(AZACYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS - 4-(azacycloalkyl)benzene-1,3-diol compounds are described corresponding to general formula (I) below: | 12-22-2011 |
20110305654 | ANHYDROUS PETROLEUM JELLY/ELASTOMER-FREE DEPIGMENTING COMPOSITIONS COMPRISING A SOLUBILIZED PHENOLIC COMPOUND - Novel dermatological depigmenting compositions, especially for topical application, contain as pharmaceutical active agents a dissolved phenolic compound, formulated as anhydrous compositions free of petroleum jelly and free of elastomer. | 12-15-2011 |
20110281913 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS - Melanocortin receptor antagonist compounds, processes for preparing them and uses thereof in human medicine and cosmetics are described. | 11-17-2011 |
20110275657 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS - Melanocortin receptor modulators, processes for preparing them and use thereof in human medicine and cosmetics are described. Melanocortin receptor modulators corresponding to formula (I): | 11-10-2011 |
20110275075 | SOX MODULATORS IN THE TREATMENT OF ALOPECIA - An in vitro method for screening candidate compounds for the preventive or curative treatment of alopecia is described. The method can include determining the capacity of a compound to modulate the expression or the activity of a SOX transcription factor. The use of modulators of the expression or the activity of the transcription factor for the treatment of alopecia is also described. Methods for the in vitro diagnosis or prognosis of the pathology are also described herein. | 11-10-2011 |
20110274727 | DEPIGMENTING TOPICAL COMPOSITIONS AND THEIR USES - Depigmenting topical compositions and their uses are described. In particular, the described compositions can provide improved effectiveness in the dermatological treatment of pigmentation, without disadvantages experienced with other known compositions. The described topical compositions can comprise, in a physiologically acceptable medium, from 3% to 10% of rucinol or one of its salts. Also described, are methods of use treating pigmentation disorders of the skin with the described compositions. | 11-10-2011 |
20110274638 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS - Compounds derived from oxoazetidine corresponding to general formula (I) | 11-10-2011 |
20110268742 | PCTP MODULATORS IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the phosphatidylcholine transfer protein (PCTP), and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 11-03-2011 |
20110263677 | GOS2 MODULATORS IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of G0/G1 switch protein 2 (GOS2), and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 10-27-2011 |
20110256078 | COSMETIC/DERMATOLOGICAL COMPOSITIONS COMPRISING NAPHTHOLIC ACID COMPOUNDS AND POLYURETHANE POLYMERS - Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein. | 10-20-2011 |
20110236893 | LGR5 MODULATORS IN THE TREATMENT OF ALOPECIA - An in vitro method of screening for candidate compounds for the preventive or curative treatment of alopecia, which comprises determining the ability of a compound to modulate the expression or the activity of the LGR5 receptor is described. The use of modulators of the expression or of the activity of this receptor for treating alopecia is also described. In addition, methods for the diagnosis or prognosis, in vitro, of this disease are described. | 09-29-2011 |
20110229423 | PACAP SIGNALING PATHWAY MODULATORS FOR TREATING INFLAMMATORY SKIN DISEASES HAVING A NEUROGENIC COMPONENT, NOTABLY ROSACEA, AND COMPOSITIONS COMPRISED THEREOF - Modulators of specific PACAP receptors are useful for treating inflammatory skin diseases having a neurogenic component, and more particularly rosacea and/or facial erythema, compositions containing these and screening methods are described for identifying PACAP signaling pathway modulators. | 09-22-2011 |
20110224243 | FZD2 Molulators in the Treatment of Alopecia - An in vitro method for screening candidate compounds for the preventive or curative treatment of alopecia is described. The method can include determining the capacity of a compound to modulate the expression or the activity of a Frizzled 2 (FZD2) transmembrane receptor. Also described, is the use of modulators of the expression or the activity of the transmembrane receptor for the treatment of alopecia. Methods for the in vitro diagnosis or prognosis of this pathology are also described. | 09-15-2011 |
20110218506 | AMOROLFINE PATCH FOR THE TREATMENT OF ONYCHOMYCOSIS - A transungual patch/device useful for the treatment of onychomycosis includes:
| 09-08-2011 |
20110213009 | ADFP MODULATORS IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the adipose differentiation-related protein (ADFP), and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 09-01-2011 |
20110189686 | SCREENING FOR MODULATORS OF CYP2B15 AND/OR GPD1 FOR THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the CYP2B15 and/or glycerol-3-phosphate dehydrogenase 1 (GPD1) proteins. | 08-04-2011 |
20110183943 | CONCURRENT THERAPY REGIME/REGIMEN FOR THE TREATMENT OF ACNE RELATED DISEASES - A novel therapy regime/regimen for the treatment of acne related diseases includes administering a topical fixed-dose combination of a retinoid and an anti-bacterial agent, such as BPO, to a course of oral antibiotic therapy. | 07-28-2011 |
20110165168 | CIDEA MODULATORS IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the CIDEA protein, and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 07-07-2011 |
20110152372 | ANHYDROUS PETROLEUM JELLY/ELASTOMER-FREE DEPIGMENTING COMPOSITIONS COMPRISING A SOLUBILIZED PHENOLIC COMPOUND AND A RETINOID - Novel dermatological depigmentation compositions, especially for topical application, contain as pharmaceutical active agents a dissolved phenolic compound and a retinoid, formulated as anhydrous compositions free of petroleum jelly and free of elastomer. | 06-23-2011 |
20110150774 | SCREENING FOR MODULATORS OF CES1 AND/OR CES3 FOR THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the carboxylesterase 1 (CES1) and/or carboxylesterase 3 (CES3) proteins. | 06-23-2011 |
20110150773 | MODULATORS OF ACETYL-COENZYME A ACYLTRANSFERASE 1 OR 2 IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of acetyl-coenzyme A acyltransferase 1 (ACAA1) or of acetyl-coenzyme A acyltransferase 2 (ACAA2), and also utilizes modulators of the expression or of the activity of either of these enzymes, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 06-23-2011 |
20110150772 | MODULATORS OF CARNITINE OCTANOYLTRANSFERASE IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of carnitine octanoyltransferase (CROT), and also utilizes modulators of the expression or of the activity of this enzyme, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 06-23-2011 |
20110135584 | PHARMACEUTICAL/COSMETIC, E.G., ANTI-ACNE COMPOSITIONS COMPRISING AT LEAST ONE NAPHTHOIC ACID COMPOUND, BENZOYL PEROXIDE AND AT LEAST ONE FILM-FORMING AGENT - Stable pharmaceutical/cosmetic compositions for topical application, notably for the treatment of acne vulgaris include, formulated into a physiologically acceptable medium, at least one naphthoic acid compound, benzoyl peroxide and at least one film-forming agent, the at least one naphthoic acid compound and the benzoyl peroxide advantageously being in a dispersed form therein. | 06-09-2011 |
20110130461 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 06-02-2011 |
20110070176 | METHOD FOR THE TREATMENT OF ACNE USING COMPOSITIONS COMPRISING 0.3% BY WEIGHT OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID - Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions. | 03-24-2011 |
20110027204 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 02-03-2011 |
20110003894 | DERMATOLOGICAL COMPOSITIONS COMPRISING RETINOIDS, DISPERSED BENZOYL PEROXIDE AND CARRAGEENANS - Dermatological compositions containing, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and at least one gelling agent of the family of the carrageenans, are useful for treating dermatological conditions and afflictions linked to disorders of cell differentiation and/or proliferation and/or keratinization, notably for treating acne vulgaris. | 01-06-2011 |
20100324111 | COMBINATION COMPRISING PYRROLIDONE-5-CARBOXYLIC ACID AND AT LEAST ONE COMPOUND FROM CITRULLINE, ARGININE AND ASPRAGINE, AND USE THEREOF IN THE TRATMENT OF ATOPIC DERMATITIS - The present invention relates to a composition comprising, in a physiologically acceptable carrier, pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, in racemic or isomer form, and salts thereof, for the preparation of a medicament for use in the treatment and/or prevention of atopic dermatitis. | 12-23-2010 |
20100292296 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS - Novel ligand compounds having the general formula (I): | 11-18-2010 |
20100286430 | METHOD FOR THE SYNTHESIS OF (Z)-3-[2-BUTOXY-3'-(3-HEPTYL-1-METHYL-UREIDO)-BIPHENYL-4-YL]-2-METHOXY-AC- RYLIC ACID - The invention relates to a process for the synthesis of (Z)-3-[2-butoxy-3′-(3-heptyl-1-methylureido)biphenyl-4-yl]-2-methoxyacrylic acid of formula (I): | 11-11-2010 |
20100286285 | Pharmaceutical composition comprising oleaginous ointments and vitamin D or its derivatives in the solubilized state - The present invention relates to an anhydrous pharmaceutical composition for use in the treatment of psoriasis and other skin disorders, characterized in that it comprises an oleaginous ointment and, as active ingredient, a compound chosen from vitamin D and its derivatives, said active agent being in a solubilized form in said composition. | 11-11-2010 |
20100280121 | PRODUCTION OF ADAPALENE GELS - A method for producing an adapalene aqueous gel on an industrial scale including formulating a gelling medium A by mixing water and propylene glycol and adding a gelling agent thereto; formulating an adapalene medium B by dispersing adapalene in water, in the presence of a surfactant; next adding the adapalene medium B to the gelling medium A; and adjusting the pH to about 4.7-5.3. | 11-04-2010 |
20100273883 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof - Novel ligand compounds having the structural formula (I): | 10-28-2010 |
20100273882 | METHOD FOR THE TREATMENT OF ACNE USING COMPOSITIONS COMPRISING 0.3% BY WEIGHT OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID - Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions. | 10-28-2010 |
20100273813 | NOVEL N-PHENYLACETAMIDE INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel N-phenylacetamide compounds of formula (I): | 10-28-2010 |
20100261754 | NOVEL RAR RECEPTOR AGONIST LIGANDS AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS - The invention relates to compounds corresponding to general formula (I) below: | 10-14-2010 |
20100260736 | EGR1 MODULATORS FOR THE TREATMENT OF ALOPECIA - An in vitro method of screening of candidate compounds for the preventive or curative treatment of alopecia includes determination of the capacity of a compound to modulate the expression or activity of the Early Growth Response 1 transcription factor (EGR1), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of alopecia; such method also includes in vitro diagnosis or prognosis of this pathology. | 10-14-2010 |
20100247583 | NOVEL N-PHENYLACETAMIDE INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel N-phenylacetamide compounds of formula (I): | 09-30-2010 |
20100247468 | Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds - Novel compounds having the general formula (I) below: | 09-30-2010 |
20100233718 | NON-INVASIVE TECHNIQUE FOR CONDUCTING SKIN INFLAMMATORY DISEASE PHARMACO-GENOMIC STUDIES AND DIAGNOSES THEREOF - Non-invasive techniques to conduct skin inflammatory disease pharmaco-genomic studies and diagnoses thereof feature discriminating biomarkers and genes and in vitro diagnostic methods employing such biomarkers. | 09-16-2010 |
20100222431 | NOVEL PHENYLUREA INHIBITORS OF THE SOAT-1 ENZYME AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel phenylurea compounds of formula (I): | 09-02-2010 |
20100222333 | EXCIPIENT PRESERVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF - Topically applicable pharmaceutical compositions contain at least one pharmaceutically active agent and an effective antimicrobial amount of a preservative excipient mixture and devoid of such amount of known preservative(s) as would otherwise itself impart an effective antimicrobial action thereto. | 09-02-2010 |
20100210994 | DELIVERY OF THERAPEUTICALLY/DERMATOLOGICALLY ACTIVE SPECIES INTO THE SKIN VIA ELECTROPORATION - A regime or regimen for treating a skin disease, disorder or condition afflicting a patient in need thereof includes forming at least one micropore to a predetermined depth through a surface of the afflicted skin of such patient; positioning at least a first electrode on the surface of the afflicted skin electrically coupled to the at least one micropore and a second electrode on the surface of the afflicted skin spaced apart from the first electrode; applying an electrical voltage from the first and second electrodes to produce a desired electroporation in the skin, and further including the step of delivering a biologically active species to the afflicted skin at the at least two micropores formed therein, wherein the biologically active species is therapeutically/dermatologically active against the skin disease, disorder or condition. | 08-19-2010 |
20100197735 | NOVEL PHENYLUREA INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel phenylurea compounds of formula (I): | 08-05-2010 |
20100190853 | TOPICAL APPLICATION OF TRAVOPROST FOR COMBATING HAIR LOSS - Travoprost medicament compositions for non-daily topical application are useful for simulating or inducing the growth and/or decreasing the loss and/or increasing the density and/or reducing the heterogeneity in the diameter of human hair shafts/follicles, e.g., for the treatment of androgenic alopecia, such medicament compositions being at least twice applied over a time interval of greater than 24 hours. | 07-29-2010 |
20100183741 | DERMATOLOGICAL COMPOSITIONS COMPRISING AT LEAST ONE RETINOID COMPOUND, AN ANTI-IRRITANT COMPOUND AND BENZOYL PEROXIDE - Dermatological compositions contain, formulated into a physiologically acceptable medium, at least one retinoid compound selected from among all-trans retinoic acid, isotretinoin, motretinide, and naphthoic acid compounds of formula (I), and salts and esters thereof: | 07-22-2010 |
20100179209 | Pactimibe medicaments for preventing/treating a disease due to sebaceous gland dysfunction in humans or animals - Administration of at least one compound selected from N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (pactimibe) of formula (I): | 07-15-2010 |
20100172957 | EFLUCIMIBE MEDICAMENTS FOR PREVENTING/TREATING A DISEASE DUE TO SEBACEOUS GLAND DYSFUNCTION IN HUMANS OR ANIMALS - Administration of at least one compound selected from (S)-2-dodecylsulfanyl-N-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetanilide (eflucimibe) of formula (I): | 07-08-2010 |
20100168241 | TREATMENT OF ACNE DISEASE STATES, NOTABLY ACNE VULGARIS - Acne disease states, notably acne vulgaris, are treated with naphthoic acid compounds and particularly adapalene in association/combination with light therapy. | 07-01-2010 |
20100168231 | TARGET ENZYME FOR THE TREATMENT OF ACNE - The use of an enzyme as a research tool for acne, by identifying a compound for the treatment of acne and/or any disorder associated with cutaneous hyperseborrhoea. | 07-01-2010 |
20100168089 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE - An in vitro method of screening for candidate compounds for the preventive or curative treatment of acne entails determination of the ability of a compound to inhibit the expression or the activity of TACE, and also to the administration of inhibitors of the expression or of the activity of this enzyme, in the treatment of acne. | 07-01-2010 |
20100166852 | Cream gels comprising at least one retinoid and benzoyl peroxide - The invention relates to a composition in the form of a cream gel comprising, in a physiologically acceptable medium, at least one dispersed retinoid and dispersed benzoyl peroxide, to its process of preparation and to its use in cosmetics and in dermatology. | 07-01-2010 |
20100160439 | DERMATOLOGICAL COMPOSITIONS COMPRISING AT LEAST ONE RETINOID COMPOUND, AN ANTI-IRRITANT COMPOUND AND BENZOYL PEROXIDE - Dermatological compositions contain, formulated into a physiologically acceptable medium, at least one retinoid compound selected from among all-trans retinoic acid, isotretinoin, motretinide, and naphthoic acid compounds of formula (I), and salts and esters thereof: | 06-24-2010 |
20100158843 | NOVEL 3-PHENYLPROPANOIC COMPOUND ACTIVATORS OF RECEPTORS OF PPAR TYPE AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel 3-phenylpropanoic acid compounds have the general formula (I) below: | 06-24-2010 |
20100145105 | NOVEL PHENYLBORONIC ACID COMPOUNDS AND INTERMEDIATES AND PROCESSES FOR THE PREPARATION THEREOF - Vitamin D derivatives, notably non-steroidal vitamin D derivatives, are prepared from novel disubstituted phenylboronic acid compounds having the formula (I): | 06-10-2010 |
20100144884 | NOVEL 3-PHENYL ACRYLIC ACID COMPOUND ACTIVATORS OF TYPE PPAR RECEPTORS AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel 3-phenyl acrylic acid compounds have the following general formula (I): | 06-10-2010 |
20100144814 | NOVEL 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF - Novel 4-phenylimidazole-2-thione tyrosinase inhibiting compounds corresponding to the following general formula (I): | 06-10-2010 |
20100144813 | NOVEL 4-HETEROARYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF - Novel 4-heteroarylimidazole-2-thione tyrosinase inhibiting compounds corresponding to the following general formula (I): | 06-10-2010 |
20100143446 | Novel skin moisturizing compositions - Novel skin moisturizing compositions are applied onto dry skin, particularly mild to moderately dry skin, are non-irritating and contain at least one natural moisturizing factor, | 06-10-2010 |
20100143445 | Dermatological/cosmetic skin depigmenting compositions - Depigmenting compositions having improved effectiveness in the dermatological or cosmetic treatment of pigmentation contain, in a physiologically acceptable medium, at least one compound selected from among rucinol and salts thereof, and at least one retinoid; such compositions are also useful in the prevention and/or dermatological treatment of skin hyperpigmentation, and also for the cosmetic treatment of photoinduced or chronological aging of the skin or of the skin appendages. | 06-10-2010 |
20100130614 | ADMINISTRATION OF ADAPALENE FOR MODULATING THE EXPRESSION OF IL-1ra - Adapalene or pharmaceutically acceptable salt thereof is administered to an individual in need of such treatment for modulating the expression of IL-1ra by the cells of acneic epidermis. | 05-27-2010 |
20100130613 | ADMINISTRATION OF ADAPALENE FOR MODULATING THE EXPRESSION OF CD1d OR IL-10 - Adapalene or pharmaceutically acceptable salt thereof is administered to an individual in need of such treatment for modulating the expression of CD1d or IL-10 in an inflammatory acneic lesion. | 05-27-2010 |
20100124538 | TOPICAL APPLICATION OF FLUOCINOLONE ACETONIDE FOR DEPIGMENTATION OF THE SKIN - Topically applicable compositions useful for the depigmentation of the skin contain a fluocinolone acetonide depigmenting agent, at a concentration of from 0.0001% to 0.02% by weight, of the total weight of the composition, formulated into physiologically acceptable carrier therefor. | 05-20-2010 |
20100099689 | METHODS OF MODULATING PPAR GAMMA-TYPE RECEPTORS - Novel compounds having the general formula (I) below: | 04-22-2010 |
20100087669 | NOVEL PHENYLBORONIC ACID COMPOUNDS AND INTERMEDIATES AND PROCESSES FOR THE PREPARATION THEREOF - Vitamin D derivatives, notably non-steroidal vitamin D derivatives, are prepared from novel disubstituted phenylboronic acid compounds having the formula (I): | 04-08-2010 |
20100069495 | Topical application of adapalene for the long-term treatment of acne vulgaris - Administration of adapalene in a topical medicament to a patient so as to sustain its biological response in the treatment of acne vulgaris, wherein the administration pattern of the topical medicament comprises topically applying onto the afflicted skin area a therapeutically effective amount of adapalene at least once every two days for at least 6 months. | 03-18-2010 |
20100057369 | Corrective methodology for processing results of transcriptome experiments obtained by differential analysis - A corrective method for processing results of transcriptome experiments obtained by differential analysis includes the following steps:
| 03-04-2010 |
20100035988 | Methods for activating PPAR gamma-type receptors - Novel biaromatic compounds having the following structural formula (I): | 02-11-2010 |
20100028879 | Modulators of HSD17b7 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of hydroxysteroid (17-beta) dehydrogenase type 7, and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or in vitro prognosis of these pathologies are also described. | 02-04-2010 |
20100028878 | Modulators of UDP-glucose ceramide glucosyltransferase for treating acne or hyperkeratinization - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of UDP-glucose ceramide glucosyltransferase (UGCG), and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperkeratinization; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 02-04-2010 |
20100022642 | Dermatological/cosmetic compositions comprising a retinoid and benzoyl peroxide - Dermatological/cosmetic compositions contain, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and a gelling system comprising at least two categories of compounds. | 01-28-2010 |
20100021893 | Modulators of lanosterol synthetase for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of lanosterol synthetase (LSS), and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 01-28-2010 |
20100021892 | Modulators of SC4MOL for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of sterol-C4-methyl oxidase (SC4MOL), and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 01-28-2010 |
20100010049 | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof - Compounds corresponding to the following general formula (I): | 01-14-2010 |
20090318550 | Emulsions comprising at least one retinoid and benzoyl peroxide - Stable dermatological/cosmetic emulsions useful, e.g., for the treatment of acne vulgaris, contain, formulated into a physiologically acceptable medium, a homogeneous dispersion of at least one dispersed retinoid, dispersed benzoyl peroxide, at least one fatty phase, at least one hydrophilic phase and at least one emulsifier. | 12-24-2009 |
20090305209 | Online protocol/tool for evaluating acne lesions - A web-based protocol/tool to improve the identification and characterization process of evaluators in recognizing and distinguishing acne lesions, included at least the following program activities:
| 12-10-2009 |
20090298798 | COMBINATIONS OF ADAPALENE AND BENZOYL PEROXIDE FOR TREATING ACNE LESIONS - Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO. | 12-03-2009 |
20090298074 | Modulators of ELOVL5 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of ELOVL5 and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 12-03-2009 |
20090281188 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 11-12-2009 |
20090258356 | Modulators of the transporter ABCD3 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of the peroxisome membrane transporter 1 comprising a type 3 ATP-binding site of the sub-family D (ABCD3), and the use of modulators of the expression or activity of this transporter for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 10-15-2009 |
20090253788 | Combinations of adapalene and benzoyl peroxide for treating acne lesions - Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO. | 10-08-2009 |
20090246776 | Modulators of scarb-1 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of the SCARB-1 receptor, and the use of modulators of the expression or activity of this receptor for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 10-01-2009 |
20090191245 | REDUCED-IRRITANT DERMATOLOGICAL COMPOSITIONS COMPRISING AT LEAST ONE NAPHTHOIC ACID COMPOUND AND BENZOYL PEROXIDE AND TREATMENT OF KERATINIZATION DISORDERS THEREWITH - Topically applicable, reduced-irritant dermatological/cosmetic compositions useful for the prevention/treatment of a variety of keratinization disorders, for example acne vulgaris, contain at least one naphthoic acid compound and an amount of benzoyl peroxide encapsulated in a polymeric system of porous particles for increasing cutaneous penetration of the at least one naphthoic acid compound, are formulated into topically applicable, physiologically acceptable media therefor. | 07-30-2009 |
20090137569 | Administration of (3S)-N-hydroxy-4-(sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide or (S)-N_hydroxy-4-[4_(but-2-ynyloxy)phenylsulfonyl]-2,2-dimethyl thimomorpholine-3-carboxamide for preventing and/or treating inflammatory skin pathologies/afflictions - Inflammatory skin pathologies/afflictions, e.g., eczema or psoriasis, are prevented and/or treated by administering to a subject in need of such treatment, a thus effective amount of at least one compound of following formula (I): | 05-28-2009 |
20090098219 | Cosmetic/pharmaceutical compositions comprising retinoids and anti-irritants and treatment of keratinization disorders therewith - Topically applicable cosmetic/pharmaceutical compositions contain at least one retinoid and at least one anti-irritant compound selected from among is allantoin, divalent strontium salts, divalent zinc salts, monovalent sodium salts and the hydrated derivatives thereof, and are useful for the treatment and/or prevention of a dermatological condition or affliction related to a disorder of keratinization relating to cell differentiation and to cell proliferation, e.g. acne vulgaris. | 04-16-2009 |
20090088460 | Administration of E-3[3-[N-(4-methoxybenzenesulfonyl)-N-isopropylamino]phenyl]-3-(3-pyridyl- )propenohydroxamic acid for preventing and/or treating inflammatory cutaneous pathologies/afflictions - Inflammatory cutaneous pathologies/afflictions, e.g., eczema or psoriasis, are prevented and/or treated by administering to a subject in need of such treatment, a thus effective amount of E-3-[3-[N-(4-methoxybenzenesulfonyl)-N-isopropylamino]phenyl]-3-(3-pyridyl)propenohydroxamic acid of formula (I): | 04-02-2009 |
20090062340 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF - Novel biaromatic compounds having the structural formula (I) below: | 03-05-2009 |
20090048289 | ADMINISTRATION OF TROPISETRON FOR TREATING INFLAMMATORY SKIN DISEASES/DISORDERS - Tropisetron or salt thereof, formulated into diverse pharmaceutical/dermatological compositions, is useful for the treatment of a variety of inflammatory skin disorders/diseases, e.g., eczema, psoriasis, rosacea, acne vulgaris, ulcers, seborrhoeic dermatitis and irritations induced by chemical, physical or mechanical agents, notably rosacea. | 02-19-2009 |
20090036536 | Biphenyl compound selective agonists of gamma RAR receptors - Biphenyl compounds having the formula (I): | 02-05-2009 |
20090023811 | Biphenyl compound selective agonists of gamma RAR receptors - Biphenyl compounds having the formula (I): | 01-22-2009 |
20090018102 | Phamaceutical/cosmetic compositions comprising hyaluronic acid and treatment of dermatological conditions therewith - Pharmaceutical/cosmetic compositions containing a dermatologically effective amount of hyaluronic acid, at least one retinoid and/or salt and/or derivative thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, formulated into a physiologically acceptable medium therefor, are useful for the treatment of wrinkles, fine lines, fibroblast depletions and scars. | 01-15-2009 |
20090012172 | Cosmetic/pharmaceutical compositions comprising retinoids and anti-irritants and treatment of keratinization disorders therewith - Topically applicable cosmetic/pharmaceutical compositions contain at least one retinoid and at least one anti-irritant compound selected from among the salts of 18β-glycyrrhetinic acid and derivatives thereof, and are useful for the treatment and/or prevention of a dermatological condition or affliction related to a disorder of keratinization relating to cell differentiation and to cell proliferation, e.g. acne vulgaris. | 01-08-2009 |
20090012129 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS - Novel biaromatic compounds that modulate peroxisome proliferator-activator receptors, known as PPAR, having the formula (I): | 01-08-2009 |
20090004232 | BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF - Physically stable pharmaceutical/cosmetic compositions contain at least one hydrophilic phase, at least one lipophilic phase and at least one active principle, e.g., at least one steroidal anti-inflammatory agent, anti-fungal agent, anti-parasitic agent, nuclear receptor modulator and/or sex steroid, said at least one active principle being present in dissolved state in each of these phases; these are formulated via characteristic multi-step methodology. | 01-01-2009 |
20080305060 | AQUEOUS-ALCOHOLIC DEPIGMENTING GELS - Stable, topically applicable cosmetic/pharmaceutical skin depigmenting compositions contain at least one phenolic compound, at least one retinoid and at least one corticoid, and are formulated as aqueous-alcoholic gels in topically applicable, physiologically acceptable media therefor. | 12-11-2008 |
20080253986 | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers - Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein. | 10-16-2008 |